<DOC>
	<DOCNO>NCT02472600</DOCNO>
	<brief_summary>This investigator initiate , international , multicenter open-label , randomize control trial aim ass whether 5 day course oral nonabsorbable antibiotic ( colistin sulfate 2 million IU per o 4x/day neomycin sulfate 500 mg ( salt ) per o 4x/day ) follow fecal microbiota transplantation ( administer either via nasogastric administration via capsule ) effective eradicate intestinal carriage beta-lactamase produce Enterobacteriaceae ( ESBL-E ) carbapenemase produce Enterobacteriaceae ( CPE ) . compare intervention ( current standard care ) adult non-immunosuppressed patient .</brief_summary>
	<brief_title>Eradication Antibiotic-resistant Bacteria Through Antibiotics Fecal Bacteriotherapy</brief_title>
	<detailed_description>In recent year certain family bacteria ( Enterobacteriaceae ) colonize human gastrointestinal tract also cause severe infection increasingly become resistant antibiotic acquire enzymes inactivate wide array valuable drug . Depending class beta-lactam antibiotic enzyme inactivate , bacteria either designate extended spectrum beta-lactamase produce Enterobacteriaceae ( ESBL-E ) carbapenemase produce Enterobacteriaceae ( CPE ) . The R-GNOSIS project finance European Commission combine five separate international clinical study ( work package 2 6 ) examine intervention strategy reduce carriage , infection spread bacteria . This study ( work package 3 R-GNOSIS ) conduct 4 center 3 European country ( Switzerland , France , The Netherlands ) Israel . The study examine whether possible eradicate intestinal carriage ESBL-E CPE administer 5 day course oral nonabsorbable antibiotic ( colistin sulfate neomycin sulfate ) follow administration `` healthy '' stool flora obtain healthy volunteer donor ( `` fecal microbiota transplantation '' FMT ) . The `` healthy '' stool flora procedure obtain carefully select healthy volunteer test wide variety infectious diseases show risk factor risky behavior transmittable disease . Once fecal material process frozen -80°C six month administration patient ( via capsule via nasogastric tube ) . FMT successfully use treat recurrent infection specific pathogen ( Clostridium difficile ) proven safe effective indication never study aim eradicate multidrug-resistant organism .</detailed_description>
	<mesh_term>Colistin</mesh_term>
	<mesh_term>Neomycin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Adult patient ( &gt; = 18 year date inclusion ) Ability provide inform consent Documented intestinal carriage ESBLE / CPE stool culture baseline ( visit 0 ) IF COLONIZED WITH ESBLE ONLY ( WITHOUT CPE ) : At least one episode symptomatic infection ESBLE require systemic antibiotic therapy within last 180 day date inclusion ( base last day antibiotic therapy infection ) Pregnancy plan pregnancy Breastfeeding Difficult / impossible followup Allergy contraindication one study drug Recurrent aspiration / chronic dysphagia Resistance colistin ( defined MIC &gt; 2 mg/l ) ESBLE CPE strain isolated baseline Estimated life expectancy &lt; 6 month Treatment systemic antibiotic day inclusion Severe immunodeficiency Systemic chemotherapy ≤30 day baseline plan chemotherapy within next 6 month Human Immunodeficiency Virus ( HIV ) CD4 count &lt; 250/mcl Prolonged use steroid ( prednisone equivalent ≥ 60 mg per day &gt; = 30 day ) immunosuppressive medication neutropenia absolute neutrophil count &lt; 1000/μL , Solid organ transplant Hematopoeitic stem cell transplant recipients Other cause severe immunodeficiency Current hospitalization Intensive Care Unit Estimated glomerular filtration rate ( CKDEPI ) &lt; 15 ml/min/1.73m2 Severe food allergy ( anaphylaxis , urticaria ) Unavailability compatible FMT preparation ( regard donor / recipient cytomegalovirus , EpsteinBarr virus toxoplasma serology ) Anatomic contraindication placement nasogastric tube ( FMT application via nasogastric tube )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>extend spectrum beta-lactamase produce enterobacteriaceae</keyword>
	<keyword>carbapenemase produce enterobacteriaceae</keyword>
	<keyword>multidrug resistant bacteria</keyword>
</DOC>